Showing all 4 results
Buy medicines for Hepatitis C – reliable drugs and treatment methods
Classic treatment regimen
Weekly injections of pegylated interferons α (alpha) and β (beta) in combination with daily oral tablets of the nonspecific antiviral chemotherapy drug ribavirin are the standard treatment algorithm, which doctors have recently begun to abandon more and more often. Interferon began to be actively used for the treatment of hepatitis C back in 1991. The purpose of interferon is explained by a simple principle – the interferon protein introduced into the body acts as a strong stimulator of the immune system and “prompts” the immune system to destroy the virus.
In the treatment can be used as standard or short IFN interferon α or β, and pegylated IFN α or β with prolonged action. A short IFN is quickly eliminated from the body, so injections (injections) should be given at least three times a week. Pegylated IFN (Peg-IFN) remains in the blood at a high concentration for 48-72 hours and therefore allows you to reduce the frequency of injections to one per week. In both cases, the individual dosage of IFN is calculated and determined only by the attending physician.
Of the standard (short) interferons in clinical practice, the following are most common:
It is more expedient to use Peg-IFN α / β – pegylated interferons α or β, about which doctors immediately warn patients. From this group, the most often prescribed:
Interferon monotherapy is rarely used. As an exception, monotherapy can be justified as an antifibrotic treatment in patients with advanced stages of liver fibrosis and cirrhosis.
This is a drug from the pharmacological group of nonspecific antiviral chemotherapy drugs. Ribavirin is successfully used in severe forms of various viral infections, since it effectively affects almost all highly pathogenic viruses, including the hepatitis C virus. Patients with hepatitis C are prescribed the drug in addition to Peg-IFN α / β.
Ribavirin is available in capsules and 200 mg tablets for oral administration. The daily dose is determined by the attending physician, based on the patient’s body weight (1,000 mg of ribavirin – if the patient’s body weight is less than 75 kg and 1,200 mg of ribavirin – if the patient’s body weight is more than 75 kg).
Buy interferon-free medicines produced in tablets
What pills for hepatitis C should be taken if the patient does not tolerate interferon and ribavirin well or, for health reasons, cannot be treated according to this scheme and needs modern interferon-free therapy? In such situations, doctors prescribe the latest antiviral drugs, inhibitors of direct antiviral action. Such drugs have a number of undeniable benefits, including:
- minimal risk of side effects;
- the minimum list of absolute contraindications;
- the shortest duration of the course of treatment;
- are as easy to use as possible;
- the most pronounced antiviral therapeutic effect.
Often, after the first week of treatment, a good clinical result and antiviral effect becomes noticeable. In 95-98% of patients, the eradication of the HCV virus and a complete cure of the disease occurs after 8 or 12 weeks of taking the latest pills.
Sofosbuvir, or Sovaldi
According to many doctors, sofosbuvir, sofosbuvir / SOF (trade name of the drug “Sovaldi”) is the best inhibitor of the NS5B protein RNA-dependent RNA polymerase of the HCV replication complex in one 400 mg tablet for the treatment of hepatitis C. medicine. The drug is pangenotypic (that is, it is effective for any genotype of the HCV virus), is one of the most effective and is used not only in Russia, but also in the USA, Europe and other countries of the world. Sofosbuvir cannot be prescribed as monotherapy, it is used only in combination with other inhibitor molecules and almost always get an excellent result.
The drug is taken once a day, at about the same time with an interval of 24 hours. A good safety profile and rare side effects allowed doctors to start using Sovaldi sofosbuvir for the treatment of acute and chronic forms of hepatitis C, even in adolescents aged 12 to 18 years with a body weight of at least 35 kilograms.
Daclatasvir, or Daklinza
Daclatasvir, daclatasvir / DCV (trade name of the drug “Daklinza”) is a pangenotypic inhibitor of the NS5A protein replicase of the HCV replication complex, which demonstrates high antiviral efficacy and safety even in patients with severe and / or complicated HCV cirrhosis, not to mention patients with chronic hepatitis C.
The standard dose of the drug is 60 mg per day, once, by mouth (orally). The drug effectively affects all 6 HCV genotypes found in clinical practice. The NS5A protein replicase inhibitor daclatasvir is combined with the NS5B inhibitor sofosbuvir (prescribed for any HCV genotype) or the NS3 / 4A inhibitor asunaprevir (prescribed for HCV genotype 1b).
Harvoni, or Ledipasvir and Sofosbuvir in one tablet 90/400 mg
Combined preparation containing two inhibitors:
- ledipasvir, ledipasvir / LDV (blocks NS5A protein replicase of HCV replication complex), 90 mg;
- sofosbuvir, sofosbuvir / SOF (blocks the NS5B protein RNA-dependent RNA polymerase of the HCV replication complex), 400 mg.
The effectiveness of Harvoni tablets is due to their ability to quickly block (inhibit) two important proteins in the HCV viral replication cycle, especially the NS5B protein, which is essential for the final completion of viral assembly.
The combined drug “Harvoni” is successfully used in the mode of primary DAA / 1 interferon-free therapy for the treatment of chronic hepatitis C disease with HCV genotypes 1, 4, 5 and 6. Take just one tablet, just once a day for 8 or 12 weeks. Patients taking Harvoni do not need to additionally prescribe ribavirin.
Epkluza, or Velpatasvir and Sofosbuvir in one tablet 100/400 mg
Are there universal pills in modern medicine that can effectively fight all six known genotypes of the HCV virus? The answer is yes. Yes! Such a drug exists, and it is recommended for use in clinical practice. The combined preparation Epkluza contains two pangenotypic inhibitors of two proteins of the HCV replication cycle:
- 1st inhibitor of NS5A replicase protein – velpatasvir (velpatasvir / VEL), 100 mg;
- 2nd inhibitor of NS5B protein RNA-dependent RNA polymerase – sofosbuvir (sofosbuvir / SOF), 400 mg.
The indisputable advantages of this unique drug for primary DAA / 1 interferon-free therapy are obvious:
- efficiency up to 98%;
- high efficiency in any (1st, 2nd, 3rd, 4th, 5th and 6th) HCV genotype;
good results even in severe patients with complicated liver cirrhosis, extrahepatic manifestations of HCV syndrome and cryoglobulinemia.
Only one Epcluse tablet (velpatasvir 100 mg / sofosbuvir 400 mg) should be taken per day. The duration of the course of treatment does not depend on the severity of the patient’s general condition and the nature of the course of the hepatitis C disease and is always 12 weeks.
Maviret, or Glecaprevir and Pibrentasvir in one tablet 100/40 mg
Ultramodern combination drug with the shortest course of treatment for primary DAA / 1 and repeated DAA / 2 interferon-free therapy, which contains two inhibitors:
- 1st pangenotypic inhibitor – glecaprevir, glecaprevir / GLE (blocks the NS3 / 4A protein serine protease of the HCV virus replication complex), 100 mg;
- 2nd pangenotypic inhibitor – pibrentasvir, pibrentasvir / PIB (blocks the NS5A protein replicase of the HCV replication complex), 40 mg.
The highest efficiency of Maviret tablets is due to their ability to inhibit (block) two very important protein-enzymes necessary for the reproduction of the hepatitis C virus.
The combined drug “Maviret” is successfully used in the mode of primary DAA / 1 interferon-free therapy for the treatment of chronic hepatitis C in the 1st, 2nd, 3rd, 4th, 5th and 6th HCV genotypes. Three tablets are taken at once, just once a day for 8, 12 or 16 weeks, depending on the characteristics of the clinical situation.
The drug “Maviret” is prescribed for both primary DAA / 1 interferon-free therapy (course of treatment 8, 12 or 16 weeks), and for repeated DAA / 2 interferon-free therapy, that is, for the retreatment of hepatitis C recurrence after unsuccessful primary DAA / 1-therapy in combinations with the drug sofosbuvir “Sovaldi” (course of treatment 12, 16 or 24 weeks).
General list of absolute contraindications for all interferon-free drugs
Modern pills, direct antiviral inhibitor drugs for primary DAA / 1 and repeated DAA / 2 interferon-free therapy are very well tolerated, rarely cause side effects, but have some contraindications. Among the absolute contraindications are the following:
- the patient is under 18 years of age;
- the patient has one or another malignant neoplasm (oncology) with a life expectancy of less than 3 years;
- pregnancy and lactation.